EUSA Pharma (EUSA)

Oncology Corporate Profile

HQ Location

1717 Langhorne-Newtown Road,Suite 201
Langhorne, PA 19047

Company Description

EUSA Pharma is a newly formed specialty pharmaceutical company headquartered in the UK which supplies medicines and medical devices across Europe through its own operations, and worldwide through a network of partners in over 40 countries.


Brand Generic Indication
Caphosol®Caphosol® is indicated for dryness of the mouth or throat (hyposalivation, xerostomia), regardless of the cause and regardless of whether the conditions are temporary or permanent. Caphosol is also indicated as an adjunct to standard oral care in treating the mucositis that may be caused by radiation or high dose chemotherapy. Relief of dryness of the oral mucosa in these conditions is associated with an amelioration of pain.
ProstaScint®capromab pendetideProstaScint® (capromab pendetide) is the murine monoclonal antibody, 7E11-C5.3, conjugated to the linker-chelator, glycyltyrosyl-(N, diethylenetriaminepentaacetic acid)-lysine hydrochloride (GYK-DTPA-HCl). The 7E11-C5.3 antibody is of the IgG1, kappa subclass (IgG1). This antibody is directed against a glycoprotein expressed by prostate epithelium known as Prostate Specific Membrane Antigen (PSMA). The PSMA epitope recognized by monoclonal antibody (MAb) 7E11-C5.3 is located in the cytoplasmic domain. Expression of this glycoprotein has not been demonstrated on any other adenocarcinomas or transitional cell cancers tested. The antibody is produced by serum-free in vitro cultivation of cells, and purified by sequential protein isolation and chromatographic separation procedures.
Quadramet®samarium Sm-153 lexidronamQuadramet® is indicated for relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan.
Soltamox®tamoxifen citrateSoltamox® solution, a nonsteroidal antiestrogen, is for oral administration. Each 5 mL solution contains 10 mg tamoxifen, equivalent to 15.2 mg tamoxifen citrate and the following inactive ingredients: ethanol, glycerol, propylene glycol, sorbitol solution, licorice flavor, aniseed flavor, purified water.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
dinutuximabmonoclonal antibodyNeuroblastomaIII
tivozanibVEGF tyrosine kinase inhibitorRenal cell carcinoma (RCC)IIIAVEO

View additional information on product candidates here »


Recent News Headlines

EUSA Pharma Files Kidney Cancer Drug In The EU

3/1/2016 12:58 pm

(PharmaTimes [UK]) Mar 1, 2016 - UK-headquartered EUSA Pharma has filed a marketing application for kidney cancer drug tivozanib with the European Medicines Agency.

AVEO and EUSA Pharma Announce Exclusive Licensing Agreement for Tivozanib in Europe

12/21/2015 06:00 pm

(Yahoo! Finance) Dec 19, 2015 - EUSA to submit marketing authorization application for tivozanib in advanced RCC in Q1 2016.

Jumpstart ASCO '15 With This Quick List of Hot Research Abstracts

5/14/2015 02:00 pm

(TheStreet) May 13, 2015 - The American Society of Clinical Oncology has provided public access to 5,000 cancer drug trial research abstracts ahead of its big annual meeting. These will be some highlights for investors.

Can MRI Be Used to Identify 'Biologically Inert' DCIS?

3/16/2015 11:01 am

(Medscape Medical News) Mar 13, 2015 - MRI of the breast can detect more biologically relevant ductal carcinomas in situ (DCIS) than mammography and could be used to stratify risk for a more targeted therapeutic approach, new findings suggest.

FDA Issues Guidance For Reusable Medical Devices Linked to 'Superbugs'

3/13/2015 04:58 pm

(The Hill) Mar 12, 2015 - The Food and Drug Administration has issued new guidance for the healthcare industry on reusable medical devices that have been linked to the spread of superbugs.

Jazz Pharma to Buy EUSA For Up to $700M

4/27/2012 04:36 pm

(Yahoo! Finance/Associated Press) Apr 26, 2012 - Drugmaker Jazz Pharmaceuticals PLC said Thursday it will buy cancer drug maker EUSA Pharma Inc. in a deal worth as much as $700 million.

Jazz Pharma to Buy EUSA For Up to $700M

4/27/2012 11:03 am

(Yahoo! Finance/Associated Press) Apr 26, 2012 - Drugmaker Jazz Pharmaceuticals PLC said Thursday it will buy cancer drug maker EUSA Pharma Inc. in a deal worth as much as $700 million.

Minimum Volatility: A Versatile ETF

3/29/2012 09:04 pm

[at Seeking Alpha] - Minimum Volatility: A Versatile ETF

EUSA Pharma Acquires Development and Commercialization Rights to ASPAREC® for Treatment of Acute Lymphoblastic Leukemia from Alizé Pharma

2/2/2012 06:20 pm

(TheStreet) Feb 2, 2012 – EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has acquired the exclusive worldwide development and commercialization rights to ASPAREC® for the treatment of acute lymphoblastic leukemia (ALL) from Alizé Pharma.

ETF Fund Flows: IWM Exceeds As Markets Soar

12/1/2011 12:00 pm

[] - IWM pull in $660 million on Wednesday, Nov.

iShares Launches Minimum Volatility ETFs

10/20/2011 03:00 pm

[ETF Database] - iShares , the largest issuer of ETFs in the U.S. by total assets, rolled out another suite of funds on Thursday that offer targeted exposure to domestic and international equity markets. The new iShares ...

Researchers Show Gains in Finding Reusable Drugs

8/18/2011 04:44 pm

(Wall Street Journal) Aug 18, 2011 - Scientists have demonstrated how a couple of repurposed drugs may have benefits in treating two conditions, inflammatory bowel disease and lung cancer.

Faith At What Cost?

6/14/2011 06:04 pm

ADVENTRX Pharmaceuticals Provides Update on ANX-514

2/15/2011 12:00 am

(ADVENTRX) Feb 15, 2011 - ADVENTRX Pharmaceuticals, Inc. today provided an update on its product candidate, ANX-514, its polysorbate 80-free formulation of docetaxel.